Incyte Corporation vs Logitech International SA — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while Logitech International SA trades at $101.34 (market cap $14.46B). The key difference: Incyte Corporation is the larger of the two by market cap, and Logitech International SA pays a 1.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Logitech International SA for 92 Days on average.
| INCY | LOGI | |
|---|---|---|
Market Cap | $22.85B | $14.46B |
Volume | 1,927,029 | 349,547 |
Sector | Health | Technology |
52-Week High | $129.93 | $126.69 |
52-Week Low | $83.80 | $85.84 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $18.35B | $12.79B |
Dividend Yield | — | 1.63% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Logitech (LOGI) trades at $102.18, down slightly (-0.22%) on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 16.28% net income margin and 35.29% ROE, supported by recent earnings beats. Recent news highlights product launches like the Zone Vibe Pro headset and a partnership with SEGA for Crazy Taxi: World Tour, indicating active business development.
The outlook is cautiously optimistic, with a consensus price target of $107 offering potential upside. Key opportunities include sustained earnings growth and new product cycles, while risks involve competitive pressures in the peripheral market and potential supply chain disruptions, as noted by the CEO addressing chip shortages (WSJ, 2026-09-30).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →